Cyclosporine (Ophthalmic)

Verify with FDA CVM →

130 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
130
Total Reports
10
Deaths Reported
770.0%
Death Rate

Active Ingredients

Cyclosporine (Ophthalmic)

Administration Routes

OphthalmicUnknownIntraocularSubcutaneous

Species Affected

Dog 129
Cat 1

Most Affected Breeds

Shih Tzu 18
Crossbred Canine/dog 12
Lhasa Apso 8
Dachshund (unspecified) 8
Terrier - West Highland White 6
Terrier - Yorkshire 5
Pug 5
Spaniel - Cocker American 5
Poodle - Miniature 4
Retriever - Labrador 4

Most Reported Reactions

Vomiting 27
Corneal ulcer 18
Lack of efficacy - NOS 16
Neurogenic keratoconjunctivitis sicca (KCS) 16
Squinting 14
Lethargy (see also Central nervous system depression in 'Neurological') 13
Ocular discharge 13
Ataxia 12
Diarrhoea 12
Abnormal Schirmer tear test 12
Emesis 11
Decreased appetite 11

Outcome Breakdown

Recovered/Normal
48 (36.9%)
Outcome Unknown
35 (26.9%)
Ongoing
33 (25.4%)
Euthanized
7 (5.4%)
Recovered with Sequela
4 (3.1%)
Died
3 (2.3%)

Data Summary

Metric Value
Total adverse event reports 130
Reports involving death 10
Case-fatality rate (reported events) 770.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Cyclosporine (Ophthalmic) Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 130 adverse event reports referencing Cyclosporine (Ophthalmic), including 10 reports in which the animal died — a 770.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Cyclosporine (Ophthalmic). Reported administration routes include Ophthalmic, Unknown, Intraocular, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Cyclosporine (Ophthalmic) reports are Dog (129 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Shih Tzu (18), Crossbred Canine/dog (12), Lhasa Apso (8) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Cyclosporine (Ophthalmic) are Vomiting (27), Corneal ulcer (18), Lack of efficacy - NOS (16), Neurogenic keratoconjunctivitis sicca (KCS) (16). Of the 130 reports with a coded outcome, Recovered/Normal is the leading category at 36.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Cyclosporine (Ophthalmic).

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial